Sandbox 123: Difference between revisions

Revision as of 21:26, 5 May 2014 view source Allison Granberry (talk \| contribs) 742 edits No edit summary ← Older edit		Revision as of 20:35, 7 May 2014 view source Allison Granberry (talk \| contribs) 742 edits No edit summary Newer edit →
Line 56:		Line 56:
	Allosteric site serves as a binding site for the substrate <scene name='36/365380/3zfz_1/7'>peptidoglycan</scene>. When the substrate binds to the <scene name='36/365380/3zfz_1/21'>allosteric site</scene> (Tyr105, Asn146, Asp295, Tyr297), a conformational change occurs at the active site, opening it and allowing catalytic action to occur.		Allosteric site serves as a binding site for the substrate <scene name='36/365380/3zfz_1/7'>peptidoglycan</scene>. When the substrate binds to the <scene name='36/365380/3zfz_1/21'>allosteric site</scene> (Tyr105, Asn146, Asp295, Tyr297), a conformational change occurs at the active site, opening it and allowing catalytic action to occur.

	The medicine, ceftaroline, mimics the substrate at the allosteric site opening the active site, allowing <scene name='36/365380/3zfz_1/22'>ceftaroline</scene> to <scene name='36/365380/3zfz_1/23'>enter and bind noncovalently</scene>.		The medicine, <scene name='36/365380/3zfz_1/24'>ceftaroline</scene>, mimics the substrate at the allosteric site opening the active site, allowing <scene name='36/365380/3zfz_1/22'>ceftaroline</scene> to <scene name='36/365380/3zfz_1/23'>enter and bind noncovalently</scene>.

Navigation menu